China suspends Bristol-Myers’ most cancers drug over findings at U.S. plant

(Reuters) – China has suspended sale, import and use of Bristol-Myers Squibb Co’s cancer drug, Abraxane, the U.S. drugmaker’s China marketing partner said on Wednesday.

The suspension by China National Medical Products Administration is based on inspection findings at Bristol-Myers’ contract manufacturing facility in the United States, partner Beigene Ltd said.

Beigene and Bristol-Myers were working to restore supply as soon as possible, said the China-based drugmaker, which signed an agreement with Bristol-Myers’ Celgene unit in 2017 to market and distribute Abraxane.

Along with remediation efforts, Bristol-Myers has applied for approval to source its supply of Abraxane for the China market from an alternative manufacturing facility, Beigene said.

(Reporting by Manas Mishra in Bengaluru; Editing by Vinay Dwivedi and Shinjini Ganguli)

Read More: | For More Business Articles | Visit Our Facebook & Twitter @kbcchanneltv | Making The Invisible, Visible

Source link

READ  Poundland sells 40,000 engagement rings forward of Valentine's Day

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker
%d bloggers like this: